CA2485751A1 - Medicament combinations of sodium channel blockers and fibrinolytics for treating ischaemic conditions - Google Patents
Medicament combinations of sodium channel blockers and fibrinolytics for treating ischaemic conditions Download PDFInfo
- Publication number
- CA2485751A1 CA2485751A1 CA002485751A CA2485751A CA2485751A1 CA 2485751 A1 CA2485751 A1 CA 2485751A1 CA 002485751 A CA002485751 A CA 002485751A CA 2485751 A CA2485751 A CA 2485751A CA 2485751 A1 CA2485751 A1 CA 2485751A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- denotes hydrogen
- denotes
- hydrogen
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10226814.2 | 2002-06-15 | ||
DE10226814A DE10226814A1 (de) | 2002-06-15 | 2002-06-15 | Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände |
PCT/EP2003/005813 WO2003105844A1 (de) | 2002-06-15 | 2003-06-04 | Arzneimittelkombinationen aus natriumkanalblockern und fibrinolytika zur behandlung ischämischer zustände |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2485751A1 true CA2485751A1 (en) | 2003-12-24 |
Family
ID=29719139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002485751A Abandoned CA2485751A1 (en) | 2002-06-15 | 2003-06-04 | Medicament combinations of sodium channel blockers and fibrinolytics for treating ischaemic conditions |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1515720A1 (de) |
JP (1) | JP2005536478A (de) |
AU (1) | AU2003250338A1 (de) |
CA (1) | CA2485751A1 (de) |
DE (1) | DE10226814A1 (de) |
WO (1) | WO2003105844A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1941879A1 (de) * | 2007-01-05 | 2008-07-09 | PAION Deutschland GmbH | Nervenschutzmittel zur Behandlung von neuronalen Schäden. |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19740110A1 (de) * | 1997-09-12 | 1999-03-18 | Boehringer Ingelheim Pharma | Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
ATE361089T1 (de) * | 2001-02-02 | 2007-05-15 | Ortho Mcneil Pharm Inc | Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin |
-
2002
- 2002-06-15 DE DE10226814A patent/DE10226814A1/de not_active Withdrawn
-
2003
- 2003-06-04 AU AU2003250338A patent/AU2003250338A1/en not_active Abandoned
- 2003-06-04 JP JP2004512748A patent/JP2005536478A/ja active Pending
- 2003-06-04 EP EP03759907A patent/EP1515720A1/de not_active Withdrawn
- 2003-06-04 WO PCT/EP2003/005813 patent/WO2003105844A1/de not_active Application Discontinuation
- 2003-06-04 CA CA002485751A patent/CA2485751A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE10226814A1 (de) | 2004-01-08 |
EP1515720A1 (de) | 2005-03-23 |
JP2005536478A (ja) | 2005-12-02 |
AU2003250338A1 (en) | 2003-12-31 |
WO2003105844A1 (de) | 2003-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2003505430A (ja) | デオキシノジリマイシンの長鎖n−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用 | |
US7803762B1 (en) | Ready-to-use bivalirudin compositions | |
JP2010526101A5 (de) | ||
CA2629312C (en) | Compositions and methods for treating cns disorders | |
US20090291913A1 (en) | FACTOR Xa INHIBITOR FORMULATION AND METHOD | |
EA019258B1 (ru) | КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ | |
JP2021519764A (ja) | 線維性疾患を処置する方法 | |
US20030235576A1 (en) | New drug combinations for the treatment of ischaemic conditions | |
CA2485751A1 (en) | Medicament combinations of sodium channel blockers and fibrinolytics for treating ischaemic conditions | |
AU2010277725B2 (en) | Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients | |
JPS6391327A (ja) | 有機化合物に関する改良 | |
ZA200106439B (en) | Use of polycyclic thiazole systems for producing medicaments for preventing or treating obesity. | |
JP2006131628A (ja) | オキシメタゾリン含有水性組成物 | |
US11364196B2 (en) | Levothyroxine formulations for oral use | |
US20040087513A1 (en) | New drug combinations based on sodium channel blockers and magnesium salts | |
JP2005516050A (ja) | 急性心筋梗塞のための複合治療 | |
US20040057947A1 (en) | Drug combinations based on magnesium salts and fibrinolytics | |
US20050113391A1 (en) | Anti-hypertensive composition and methods of treatment | |
Flanagan | Tranexamic acid tamponade to control postoperative surgical hemorrhage | |
CA2491217A1 (en) | New drug combinations based on sodium channel blockers and magnesium salts | |
KR20120089444A (ko) | 정맥내 이부프로펜에 의한 위독한 환자의 치료방법 | |
CA2491712A1 (en) | New drug combinations based on magnesium salts and fibrinolytics | |
NZ230742A (en) | Thrombolytic composition comprising a plasminogen activator (tpa, uk or sk) and a thromboxane receptor antagonist; kits thereof; and process for preparation thereof | |
JPH02243634A (ja) | 虚血後の心筋機能不全回復用医薬組成物 | |
EP0431277A1 (de) | Mischung eines Thromboxan-A2-Antagonisten mit einem thrombolytischen Mittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |